BioPharma Dive June 24, 2024
Detailed data from a Phase 3 trial of the company’s “Mim8” drug showed treatment controlled bleeding at both once-weekly and once-monthly doses.
Dive Brief:
- Novo Nordisk on Sunday disclosed detailed clinical trial results for an experimental hemophilia treatment dubbed Mim8, showing once-weekly and once-monthly doses of the antibody drug controlled bleeding in people with the more common “A” form of the disorder.
- The data, which were presented at the International Society on Thrombosis and Haemostasis Annual Congress in Thailand, fill in a positive picture for Mim8’s effectiveness and safety. Novo had said in May that the Phase 3 trial, called Frontier-2, succeeded and shared topline findings.
- Among people who had not previously been on preventive treatment, researchers reported zero...
Today's Sponsors
Today's Sponsor